Published on 14 Aug 2023 on Simply Wall St. via Yahoo Finance
Brokers Are Upgrading Their Views On Repare Therapeutics Inc. (NASDAQ:RPTX) With These New Forecasts
Shareholders in Repare Therapeutics Inc. (NASDAQ:RPTX) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with analysts modelling a real improvement in business performance. The market may be pricing in some blue sky too, with the share price gaining 19% to US$9.74 in the last 7 days. Could this upgrade be enough to drive the stock even higher?
After the upgrade, the consensus from Repare Therapeutics' nine analysts is for revenues of US$65m in 2023, which would reflect a stressful 61% decline in sales compared to the last year of performance. Losses are supposed to balloon 3,205% to US$2.42 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$45m and losses of US$2.82 per share in 2023. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.
See our latest analysis for Repare Therapeutics